Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neonervin is an oral dietary supplement developed by Grand Medical Group, formulated as capsules and an oral solution. It is designed to support cardiovascular and neurological health, specifically targeting peripheral nerve damage, neuropathic pain, paresis, and cognitive decline. Neonervin contains a combination of active ingredients, including alpha-lipoic acid (an antioxidant that protects blood vessels and peripheral nerves), cytidine-5-monophosphate (CMP) disodium and uridine 5′-triphosphate (UTP) trisodium (nucleotides that activate P2Y receptors to promote myelin sheath regeneration and synaptogenesis), meclofenoxate (a cholinergic nootropic that increases acetylcholine levels and clears lipofuscin), and magnesium L-threonate (a highly bioavailable form of magnesium that crosses the blood-brain barrier to enhance synaptic density and cognitive function).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neonervin.